The trademark BiCE was filed by Commit Biologics ApS, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on June 20, 2022, and received one opposition filed on September 20, 2022 by Affimed GmbH on Likelihood of confusion. the opponent was represented by SIMMONS & SIMMONS LLP and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued September 20, 2022
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).
The Opposition with reference B 003179189 was rejected according to Article 8(1)(b) EUTMR with decision issued on December 11, 2023 by the EUIPO.
Goods And Services
The mark was filed in class 1 with Chemical, biochemical, biological and biotechnical preparations, namely, antibodies, and bi- and multispecific antibodies and fragments thereof, in the nature of monoclonal antibodies, their derivatives or conjugates for in vivo or in vitro scientific and industrial research and development related to diseases and active chemical ingredients for use in the manufacture of pharmaceutical preparations for treating cancer, infectious diseases, and autoimmune diseases..
The mark was filed in class 5 with Pharmaceutical and veterinary preparations, including pharmaceutical preparations based on antibodies, and bi- and multispecific antibodies and fragments, including monoclonal antibodies, their derivatives or conjugates, for use in diseases.
The mark was filed in class 42 with Medical and biological research, in particular research into antibodies and bi- and multispecific antibodies or fragments, including monoclonal antibodies, their derivatives or conjugates, and the development of pharmaceutical products based on antibodies and bi- and multispecific antibodies or fragments, including monoclonal antibodies, their derivatives or conjugates and Chemical analysis..